Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer

• Published in: British journal of surgery Vol. 108; no. 6; pp. 709 - 716
• Main Authors: Weniger, M, Hank, T, Qadan, M, Ciprani, D, Michelakos, T, Niess, H, Heiliger, C, Ilmer, M, D'Haese, J G, Ferrone, C R, Warshaw, A L, Lillemoe, K D, Werner, J, Liss, A, Fernández-Del Castillo, C
• Format: Journal Article
• Language: English
• Published: England 22-06-2021
• Subjects: Aged; Anti-Bacterial Agents - therapeutic use; Bile - microbiology; Female; Humans; Kaplan-Meier Estimate; Klebsiella Infections - complications; Klebsiella Infections - drug therapy; Klebsiella pneumoniae; Male; Pancreatic Neoplasms - microbiology; Pancreatic Neoplasms - mortality; Pancreatic Neoplasms - surgery; Pancreaticoduodenectomy; Prognosis; Quinolones - therapeutic use; Retrospective Studies; Survival Analysis
• ISSN: 1365-2168
• DOI: 10.1002/bjs.12003

An increasing body of evidence suggests that microbiota may promote progression of pancreatic ductal adenocarcinoma (PDAC). It was hypothesized that gammaproteobacteria (such as Klebsiella pneumoniae) influence survival in PDAC, and that quinolone treatment may attenuate this effect.
This was a retrospective study of patients from the Massachusetts General Hospital (USA) and Ludwig-Maximilians-University (Germany) who underwent preoperative treatment and pancreatoduodenectomy for locally advanced or borderline resectable PDAC between January 2007 and December 2017, and for whom a bile culture was available. Associations between tumour characteristics, survival data, antibiotic use and results of intraoperative bile cultures were investigated. Survival was analysed using Kaplan-Meier curves and Cox regression analysis.
Analysis of a total of 211 patients revealed that an increasing number of pathogen species found in intraoperative bile cultures was associated with a decrease in progression-free survival (PFS) (-1·9 (95 per cent c.i. -3·3 to -0·5) months per species; P = 0·009). Adjuvant treatment with gemcitabine improved PFS in patients who were negative for K. pneumoniae (26·2 versus 15·3 months; P = 0·039), but not in those who tested positive (19·5 versus 13·2 months; P = 0·137). Quinolone treatment was associated with improved median overall survival (OS) independent of K. pneumoniae status (48·8 versus 26·2 months; P = 0·006) and among those who tested positive for K. pneumoniae (median not reached versus 18·8 months; P = 0·028). Patients with quinolone-resistant K. pneumoniae had shorter PFS than those with quinolone-sensitive K. pneumoniae (9·1 versus 18·8 months; P = 0·001).
K. pneumoniae may promote chemoresistance to adjuvant gemcitabine, and quinolone treatment is associated with improved survival.